Tuberculosis research meeting in Bahia  by Netto, Eduardo Martins
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the  multidrug-resistant tuberculosis (MDR-TB) constitutes anor the past three years Bahia has the opportunity to sponsor
he  Tuberculosis Research Meeting in Bahia. These meetings
re  responses to the need of increasing the quantity and
uality  of research in tuberculosis. In this last meeting Dr.
hristian  Lienhardt from the WHO  tuberculosis program pre-
ented  impressive and convincing ﬁgures of the impossibility
f  eliminating tuberculosis without a tripod: new vaccine
trategy (preventing new infections), new drug therapy (to
reat  diseased and infected) and diagnostic tools (to target
hose  who need quickly and efﬁciently). They are coming; this
s  my optimistic view for the human intelligence. An example
f  these efforts was  the release of the ﬁrst drug against resis-
ant  tuberculosis approved (Bedaquiline) in December 2012
y  the FDA after more  than 50 years waiting. There are sev-
ral  more  in the second and third clinical trial phases of the
esearch  pipeline. Good news!
Tuberculosis numbers are falling. “The Millennium Devel-
pment  Goal (MDG) target to halt and reverse the TB epidemic
y  2015 has already been achieved. New cases of TB have been
alling  for several years and fell at a rate of 2.2% between 2010
nd  2011” says the 2012’s Global Report of Tuberculosis from
he  World Health Organization, most impressing is also the
umber  of collaborators of the Report, it takes four pages,
his  is truly collaboration! This is truly a coordinated effort to
liminate  this plague. Numbers are falling but we are still not
uite  there. This is the meaning of the tuberculosis research
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Este é um artigo Open Access sob a licença meeting in Bahia (EPTBa), to gather together Brazilian
researchers who are interested in this effort.
The ﬁrst EPTBa was  coordinated by Dr. Sérgio Arruda from
Centro  de Pesquisas Gonc¸alo  Moniz of the Fundac¸ão  Oswaldo
Cruz,  in 2011, Dr. Songeli Freire from the Instituto de Ciências
da’Saúde from Universidade Federal da Bahia coordinated the
second  and I had the opportunity to coordinate this third one.
The  idea to publish these ﬁve reviews was to present a bit of
history  and the present status of tuberculosis research from
Brazilians,  in a Brazilian journal.
Dr. Oliveira together with others from the National tuber-
culosis  control programme  reviewing the last ten years of
the  tuberculosis epidemiology in Brazil raises the obstacles,
together with the improvements, in controlling tuberculosis
in  Brazil. On their turn, Dr. Kritski and colleagues assessing
diagnostic tools on tuberculosis remarks that “research and
practice  clinical processes are intertwined and the main out-
comes  to be considered are the patient’s health and actions
creating  a more  effective health system in which the new
technology will be incorporated”. The third paper reviews
the  present status of the art of resistance, were  Drs. Lemos
and  Matos from the Universidade Federal da Bahia and State
Program  of Tuberculosis Resistance report the problem thatPI, Núcleo Hospitalar de Infectologia – NHE, Rua Augusto Viana,
important public health issue with the still low cure rate,
calling  to our attention the presence of new drugs and the
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recent approved Bedaquiline. Drs. Coelho-Filho, Takenami and
Arruda  reviewing the Rick formula on tuberculosis granu-
loma  state “that the balance between the characteristics of
the  bacillus and host protective response is necessary to indi-
cate  the outcome of pathogenesis, infection or active disease
and  the necrosis degree of the tuberculosis lesion” open-
ing  space for more  research on this area. And closing Dr.
Leite  reviews the contributions of one of the oldest Brazilian 1 3;1 7(2):123–124
specialized intuitions in research and patient care in Bahia,
maybe  in Brazil, remarking the fundamental ﬁgure of
Dr.  José Silveira in bringing to Brazil drugs at that time
being tested, the mass vaccination defense when peo-
ple  were  afraid of using it and other improvements that
put  Brazil in the frontier of the tuberculosis research.
Good reading and welcome to the next meeting in July
2013.
